TITLE

Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer

AUTHOR(S)
Russo, Giulia; Cioffi, Giovanni; Di Lenarda, Andrea; Tuccia, Fausto; Bovelli, Daniella; Di Tano, Giuseppe; Alunni, Gianfranco; Gori, Stefania; Faggiano, Pompilio; Tarantini, Luigi
PUB. DATE
October 2012
SOURCE
Internal & Emergency Medicine;Oct2012, Vol. 7 Issue 5, p439
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
80124798

 

Related Articles

  • The role of anthracyclines in the treatment of early breast cancer. Greene, John; Hennessy, Bryan // Journal of Oncology Pharmacy Practice;Jun2015, Vol. 21 Issue 3, p201 

    We review the use of anthracyclines, their associated cardiotoxicity, and the role of taxanes in the treatment of early breast cancer. The efficacy of anthracyclines has been proven in multiple large cohort trials and meta-analyses. The addition of a taxane to an anthracycline-based regimen in...

  • Trastuzumab.  // Reactions Weekly;11/14/2009, Issue 1278, p29 

    The article describes the case of a woman who developed thrombocytopenia while receiving trastuzumab-based adjuvant chemotherapy for breast cancer. The patient experienced a decreased platelet count but returned to normal after treatment with corticosteroids. Her chemotherapy consists of...

  • Chemotherapy in breast cancer.  // British Medical Journal;10/9/1976, Vol. 2 Issue 6040, p832 

    Examines the reaction of the media on the coverage of using adjuvant chemotherapy in breast cancer. Status of adjuvant chemotherapy in early breast cancer; Types of drugs in the treatment of cancer contributing the risk of developing other cancers; Properties of drugs.

  • Use of N-Terminal Pro-Brain Natriuretic Peptide to Assess Left Ventricular Function after Adjuvant Doxorubicin Therapy in Early Breast Cancer Patients. Cil, Timucin; Kaplan, Ali M.; Altintas, Abdullah; Akin, Ata M.; Alan, Sait; Isikdogan, Abdurrahman // Clinical Drug Investigation;2009, Vol. 29 Issue 2, p131 

    Background and objective: Anthracyclines are well established and highly efficacious antineoplastic agents for various haematopoietic and solid tumours, such as breast cancer. The main adverse effect of anthracycline therapy is cardiotoxicity. The aim of this prospective study was to determine...

  • Trastuzumab and cardiotoxicity: Weighing the risks. Siu-Fun Wong // American Journal of Health-System Pharmacy;3/15/2006, Vol. 63 Issue 6, p525 

    The article discusses the risk of cardiotoxicity associated with trastuzumab, a component of various chemotherapy regimens that has been widely accepted by the oncology community as a therapeutic option for women with metastatic breast cancer. Attention is given questions raised by Kabe and...

  • Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Costa, R. B.; Kurra, G.; Greenberg, L.; Geyer, C. E. // Annals of Oncology;Nov2010, Vol. 21 Issue 11, p2153 

    Background: Trastuzumab-based adjuvant therapy has become the standard of care for human epidermal growth factor receptor-2 (HER2)-positive early breast cancer (EBC). Both anthracycline- and non-anthracycline-containing trastuzumab regimens are approved in the United States, but cardiotoxicity...

  • Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. Montemurro, Filippo; Rossi, Valentina; Nolè, Franco; Redana, Stefania; Donadio, Michela; Martinello, Rossella; Verri, Elena; Valabrega, Giorgio; Rocca, Maria Cossu; Jacomuzzi, Maria Elena; Viale, Giuseppe; Sapino, Anna; Agliettaa, Massimo // Oncologist;Jul2010, Vol. 15 Issue 7, p665 

    Anthracyclines are among the most active drugs in breast cancer. Because of excessive cardiotoxicity, their use in combination with trastuzumab has been discouraged in patients with human epidermal growth factor receptor (HER)-2+ metastatic breast cancer. We sought to describe how this treatment...

  • Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy. Mortimer, Joanne; Jung, Jae; Yuan, Yuan; Kruper, Laura; Stewart, Daphne; Chung, Samuel; Yu, Kim; Mendelsohn, Mary; D'Apuzzo, Massimo; Tegtmeier, Bernard; Dadwal, Sanjeet // Breast Cancer Research & Treatment;Dec2014, Vol. 148 Issue 3, p563 

    We report a series of breast cancer patients with invasive skin and nail infections with Staphylococcus species that we attribute to the addition of pertuzumab to trastuzumab-based therapy. With the suspicion of an increased incidence of cutaneous infection in patients treated with pertuzumab...

  • Trastuzumab: Cardiotoxicity: 3 case reports.  // Reactions Weekly;Jun2019, Vol. 1756 Issue 1, p331 

    The article presents a case study of three women who developed cardiotoxicity following chemotherapy with trastuzumab for breast cancer.

  • Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Stoodley, Paul W.; Richards, David A.b.; Boyd, Anita; Hui, Rina; Harnett, Paul R.; Meikle, Steven R.; Clarke, Jillian L.; Thomas, Liza // European Heart Journal - Cardiovascular Imaging;Mar2013, Vol. 14 Issue 3, p228 

    Aims The benefits from anthracycline chemotherapy are undermined by potentially life-threatening cardiotoxicity. Transthoracic echocardiography is the most commonly used method for monitoring cardiotoxicity, and centres on the measurement of left ventricular systolic function. The aim of this...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics